BSE filing, NSE: GUJTHEM. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Themis Biosyn Ltd: key numbers
- Share price
- ₹371.80
- Market cap
- ₹4,839 Cr
- Revenue (annual)
- ₹165.8 Cr
- Net profit (annual)
- ₹46.68 Cr
- P/E (TTM)
- 99.4×Sector 46.1×
- Promoter holding
- 59.33%-11.53% QoQ
- FII holding
- 3.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Themis Biosyn Ltd
All →Gujarat Themis Biosyn Board Meeting Date
Gujarat Themis Biosyn scheduled its board meeting for 4 Nov 2026 to approve Q2 and H2 un-audited results. No financial figures are disclosed in this advance intimation.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn clarified that its 9 October 2026 credit-rating intimation was uploaded in error and should be disregarded. No substantive business event is reported.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn Limited submitted the mandatory quarterly compliance certificate under SEBI Regulation 74(5) regarding dematerialization of shares for the quarter ended September 30, 2026.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn Ltd held its 45th Annual General Meeting on September 30, 2026, to deliberate on ordinary and special business resolutions.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Acquisition Worth ₹1,300 Cr
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
- Value
- ₹1,300 Cr
Other other announcement announcements
All →KRN Heat Exchanger and Refrigeration Other Announcement
KRN Heat Exchanger filed its Reg 32 statement confirming no deviation in QIP fund use, with INR 349.99 Crore raised on 1 June 2026. The utilisation table reports no variation across the three objects.
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
NIIT Learning Systems Other Announcement
NIIT Learning Systems board recommended appointing Price Waterhouse Chartered Accountants LLP as statutory auditor for five years from the 25th AGM. The incumbent S. R. Batliboi firm completes its second term.
- Execution
- Five consecutive years, from the 25th AGM (2027) until the 30th AGM (2032)
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Magson Retail & Distribution Other Announcement
Magson Retail submitted its Regulation 76 Reconciliation of Share Capital Audit Report for the quarter ended 30 September 2026. The report shows a 9,15,940 share difference between issued and listed capital, pending exchange listing approval.
Ekennis Software Service Other Announcement
Ekennis Software declared Regulation 23 related party transaction rules non-applicable for H1 FY27, as its paid-up capital and net worth are below SME thresholds. A CA certificate confirms the figures.